Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Amit Sanyal, MD: A Clinician’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Jul
25
Today In Oncology
Cancer Survivors and Providers Differ on Cannabis Risk Awareness and Communication
Paraneoplastic Neurological Syndromes Associated With Improved Survival in SCLC
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo